A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623 ·Status: RECRUITING

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775 ·Status: COMPLETED ·Phase: PHASE2

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

NCT06629428 ·Status: RECRUITING ·Phase: EARLY_PHASE1

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01707992 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

NCT00097188 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

NCT07220252 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

NCT07211633 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292 ·Status: RECRUITING ·Phase: PHASE3

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 ·Status: RECRUITING ·Phase: PHASE3

An Extension of the TG1101-RMS201 Trial

NCT03381170 ·Status: COMPLETED ·Phase: PHASE2

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248 ·Status: RECRUITING ·Phase: PHASE2

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

NCT06143514 ·Status: RECRUITING

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

NCT01067521 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis

NCT00087529 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

NCT04480307 ·Status: COMPLETED ·Phase: PHASE2

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

NCT01199640 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504 ·Status: RECRUITING ·Phase: PHASE3

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148 ·Status: COMPLETED ·Phase: PHASE2

Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

NCT00086671 ·Status: COMPLETED ·Phase: PHASE2

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

NCT01803867 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963 ·Status: RECRUITING ·Phase: PHASE3